Dr Reddy’s runs into trouble with its weight-loss drug
- Posted on July 14, 2026
- By Financial Times
- 0 Views
- 1 min read
Dr Reddy's Laboratories faces significant regulatory and commercial obstacles regarding its weight-loss medication portfolio. The pharmaceutical company encounters challenges in market approval, competitive pressures, and safety evaluations. Meanwhile, the UK-India bilateral trade agreement officially commences this week, potentially opening new opportunities for pharmaceutical trade between nations and strengthening economic ties in the healthcare sector.
Summary auto-generated by AI from the original publisher's content. Editorial standards.